The effect of high-dose inhaled budesonide on lipid profile in asthmatic patients

Yavuz Ö., Türktaş I., ÇEVİK C.

General Pharmacology, vol.27, no.1, pp.89-90, 1996 (Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 1
  • Publication Date: 1996
  • Doi Number: 10.1016/0306-3623(95)00119-0
  • Journal Name: General Pharmacology
  • Journal Indexes: Scopus
  • Page Numbers: pp.89-90
  • Lokman Hekim University Affiliated: Yes

Abstract

1. We determined the effect of high doses of inhaled corticosteroid (budesonide, BUD, 1600 μg/day for 4 weeks) on fasting triglyceride, cholesterol and high-density lipoprotein (HDL)-cholesterol concentration in 11 asthmatic patients. 2. No significant change of serum fasting triglyceride concentrations was found before and after BUD therapy (p > 0.05). However, serum fasting cholesterol concentrations decreased slightly (p = 0.03) and HDL-cholesterol concentrations increased after BUD therapy for four weeks (p = 0.01). 3. These results suggest that high-dose BUD therapy does have minor effects on lipid metabolism after long periods of use in asthmatic patients.